RxDoctor Payments Data

Misbah Farooqi, MD

Internal Medicine · Blountstown, FLNPI 1710986286

Payments from drug & device makers

$3,139in general payments, 2019–2025

Across 222 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$744
  • Astellas Pharma US Inc$359
  • Amgen$308
  • AstraZeneca$242
  • Bayer$175
  • AbbVie$174
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,87492%
  • Education$2658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,139 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$35,622
Medicare patients
109
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide336$410,414
EliquisApixaban673$377,084
JardianceEmpagliflozin316$222,659
FarxigaDapagliflozin Propanediol213$176,456
LinzessLinaclotide232$149,047
MounjaroTirzepatide107$135,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$96,176
NuplazidPimavanserin Tartrate26$63,912
Tresiba Flextouch U-100Insulin Degludec166$60,629
EntrestoSacubitril/Valsartan63$55,672
VraylarCariprazine Hcl44$54,403
RexultiBrexpiprazole35$52,757
Tresiba Flextouch U-200Insulin Degludec42$48,250
TrulicityDulaglutide38$45,868
TradjentaLinagliptin64$42,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$744$424,262351 claims
PfizerEliquis$85$377,084673 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat$85$291,161425 claims
AbbVieLinzess, Vraylar, Creon, Qulipta$174$244,660312 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$242$229,805327 claims
Lilly USA, LLCMounjaro, Trulicity$145$181,809145 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$47$130,758186 claims
MerckJanumet, Janumet Xr, Januvia$31$97,622172 claims
NovartisEntresto$66$55,67263 claims
Astellas Pharma US IncMyrbetriq$359$24,35090 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$22,66046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Blountstown

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →